- Other degenerative brain diseases such as Alzheimer's
- Co-development & exclusive right of domestic sales and distribution

- Acute neurological disease and neurodegenerative disease, etc.
- Co-development & exclusive right of worldwide production and distribution on NG101’s drug substance(DS) and drug product(DP).

- Gene transfer and increased expression in vivo
- Co-development of ElectroPorator

- Patented technology for gene transfer and increased expression in vivo
- Development and production of normal human cell lines for biopharmaceutical research/production

- Chronic renal failure and ischemic heart disease

- Tissue regeneration (95% similar to human DNA)/PDRN-based specialty drug development and commercialization

- Promoting new development through strategic cooperation between REYON Pharmaceutical, FINZELBERG, and G&P for various indications

- Technical transfer of a patented technology of antifungal agent ‘iN-EYD’ of the new mechanism of action

- Co-development of pDNA-based cancer vaccine for ovarian cancer

- Co-development of iPSC-derived NK Cell therapy for solid tumor
- Supply of pDNA Drug Substance for producing NK Cell Therapy